glp 1 agonist drug list America's Poison Centers list of glp-1 agonists GLP-1

The FDA has approved specific combinations (e.g., linagliptin + dulaglutide) for this purpose, reinforcing clinical acceptance

Once daily injectable liraglutide (marketed as Victoza for T2DM and Saxenda for obesity) and once weekly injectable semaglutide (marketed as Ozempic for T2DM and Wegovy for obesity) are two additional GLP-1 analogues, sharing 97% and 94% amino acid homology to GLP-1, respectively [ Figure 2 , Table 1 ]

Approved doses of oral semaglutide range from 3 mg to 14 mg and subcutaneous semaglutide doses range from 0.25 mg to 2.4 mg, with higher doses being used for weight loss rather than glycemic control

Wang Z, Zhao Y, Zhang L

Aung MM, et al

[3] [4] Despite the absence of confirmed human cases directly attributable to GLP-1 therapy, the FDA requires this warning as a precautionary measure for many GLP-1 medications